Appointments at Merck & Co, MediGene and Medivation, as well as departures at Bristol-Myers Squibb and KV Pharmaceutical – People on the move
Julie Gerberding has been named president of Merck Vaccines, a unit of US drugmaker Merck & Co. The appointment, which is effective from January 25, will see Dr Gerberding head up the company's $5 billion global vaccine business
Previously, Dr. Gerberding led the Centers for Disease Control and Prevention (CDC) as director from 2002 to 2009, guiding the agency through more than 40 emergency response initiatives for health crises including anthrax bioterrorism, food-borne diseaseoutbreaks, and natural disasters,
Bristol-Myers Squibb (BMS) CFO Jean-Marc Huet will leave his position at the end of the year to take up an equivalent position at consumer products group Unilever.
Huet will be replaced on an interim basis at by Charles Bancroft who joined BMS in 1984, most recently serving as vice president, finance for global pharmaceutical operations.
German biotech firm MediGene has nominated Thomas Werner for its supervisory board. If elected at the next AGM, Dr Werner will help guide the firm’s development based on his considerable experience in the pharma and biotechnology sectors.
This experience includes times as CEO of GlaxoWellcome Germany, various management positions at Bristol-Myers Squibb and, more recently, as partner at venture capital group Venture Partner Inventages.
Drug developer Medivation says CFO Patrick Machado will transition to a new role, chief business officer (CBO), to oversee strategic planning, business development, alliance management and intellectual property.
The firm has also hired former Pfizer employee Karen Reeves as SVP of clinical development and appointed Bryan Selby as VP of biometrics and Vandana Date as VP of intellectual property.
Ronald Kanterman has step down for the directorial board of troubled drugmaker KV Pharmaceutical according to a regulatory filing. Earlier this year Kanterman resigned as the company’s chief financial officer in September.
Earlier this month, both KV CEO David Van Vliet and Greg Divis, president of the firm’s Ther-Rx unit, agreed to one-year contracts.
